Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityNo recent work listed

Ye Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0002-5110-5454; OpenAlex author ID A5100339238. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper

Papers 8

  1. Development and validation of a tissue-based DNA methylation risk-score model to predict the prognosis of surgically resected pancreatic cancer patients. Co-author DOI 10.21037/gs-22-517↗
  2. Fam83D promotes tumorigenesis and gemcitabine resistance of pancreatic adenocarcinoma through the Wnt/β-catenin pathway. Co-author DOI 10.1016/j.lfs.2021.119205↗
  3. Development and Validation of a Nomogram Based on Nutritional Indicators and Tumor Markers for Prognosis Prediction of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.682969↗
  4. CXCL9 chemokine promotes the progression of human pancreatic adenocarcinoma through STAT3-dependent cytotoxic T lymphocyte suppression. Co-author DOI 10.18632/aging.102638↗
  5. miR-939-5p Contributes to the Migration and Invasion of Pancreatic Cancer by Targeting ARHGAP4. Co-author DOI 10.2147/ott.s227644↗
  6. Selective activation of tumor-suppressive MAPKP signaling pathway by triptonide effectively inhibits pancreatic cancer cell tumorigenicity and tumor growth. Co-author DOI 10.1016/j.bcp.2019.05.010↗
  7. Methylation of BNIP3 in pancreatic cancer inhibits the induction of mitochondrial-mediated tumor cell apoptosis. Co-author DOI 10.18632/oncotarget.18736↗
  8. HIF-2α promotes epithelial-mesenchymal transition through regulating Twist2 binding to the promoter of E-cadherin in pancreatic cancer. Co-author DOI 10.1186/s13046-016-0298-y↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Haoran Li · 2 shared papers, 2021–2022 · strength 0.28
  2. Yuchen Tang · 2 shared papers, 2021–2022 · strength 0.28
  3. Bin Yi · 2 shared papers, 2021–2022 · strength 0.28
  4. Luming Liu · 2 shared papers, 2020–2021 · strength 0.27
  5. Jian Yang · 3 shared papers, 2016–2021 · strength 0.25
  6. Jian Zhou · 3 shared papers, 2016–2021 · strength 0.25
  7. Huifeng Gao · 2 shared papers, 2020 · strength 0.24
  8. Zhiqiang Meng · 2 shared papers, 2020 · strength 0.24
  9. Jie Wang · 1 shared paper, 2022 · strength 0.16
  10. Jian Yang · 1 shared paper, 2022 · strength 0.16
  11. Zixiang Zhang · 1 shared paper, 2022 · strength 0.16
  12. Yongqiang Hua · 1 shared paper, 2021 · strength 0.15
  13. Zhouyu Ning · 1 shared paper, 2021 · strength 0.15
  14. Weidong Shi · 1 shared paper, 2021 · strength 0.15
  15. Ke Zhang · 1 shared paper, 2021 · strength 0.15
  16. Dechun Li · 2 shared papers, 2016–2017 · strength 0.13
  17. Dongming Zhu · 2 shared papers, 2016–2017 · strength 0.13
  18. Yi Zhang · 2 shared papers, 2016–2017 · strength 0.13
  19. Yehua Shen · 1 shared paper, 2020 · strength 0.13
  20. Gang Chen · 1 shared paper, 2020 · strength 0.13
  21. Liping Zhuang · 1 shared paper, 2020 · strength 0.13
  22. Peng Du · 1 shared paper, 2021 · strength 0.12
  23. Dongming Zhu · 1 shared paper, 2021 · strength 0.12
  24. Yujie Huang · 1 shared paper, 2021 · strength 0.12
  25. Hao Chen · 1 shared paper, 2020 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.